373 related articles for article (PubMed ID: 36801605)
1. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O; Tomasini P; Radj G; Guisier F; Monnet I; Ricordel C; Bigay-Game L; Geier M; Chouaid C; Daniel C; Swalduz A; Toffart AC; Doubre H; Peloni JM; Moreau D; Subtil F; Grellard JM; Castera M; Clarisse B; Martins-Lavinas PH; Decroisette C; Greillier L;
Eur J Cancer; 2023 Apr; 183():38-48. PubMed ID: 36801605
[TBL] [Abstract][Full Text] [Related]
2. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN; Patel JD; Wakelee HA; Levy BP; Borghaei H; Pellini B; Costello MR; Dowell JE; Finley G; Huang CH; Neal JW; Nieva JJ; Puri S; Socinski MA; Thomas C; Ross EA; Litwin S; Clapper ML; Treat J
Clin Lung Cancer; 2023 Nov; 24(7):e242-e246. PubMed ID: 37451930
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A
JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426
[TBL] [Abstract][Full Text] [Related]
4. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
[TBL] [Abstract][Full Text] [Related]
7. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
9. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract][Full Text] [Related]
12. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
15. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
17. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Tani T; Naoki K; Yasuda H; Arai D; Ishioka K; Ohgino K; Yoda S; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Soejima K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1065-1071. PubMed ID: 31493177
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
